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ABSTRACT : To clarify the effectiveness of OK-432, immunopotentiator was 
intravenously used. The tumor-bearing host was apparently stimulated via NK activ-
ity and increased the number of T cells and B cells. It helps immunodepressed host 
to level up quickly. 
  However, further effective immunostimulation beyond the normal range could not 
be expected. A new combined method should be found to be immunopotentiated even 
for the uncompromized host. Recently, a new immunostimulant derived from strept-
ococcus, OK-432, was widely used for the treatment of cancer in Japan. The cyto-
static and cytotoxic actions of OK-432 for cancer cells have been made clear by in 
vitro and vivo study. It, however, is not clear as to how the developing immuno-
stimulated states differ on the condition of admistering route, dosis or time-intlrval. 
    In this series, the effects of intravenous administration of OK-432 as the host 
immunostimulator were compared with those of conventional subcutaneous admini-
stration.
   MATERIAL AND METHOD 
 Forteen patients with cancers of the 
digestive tract, in stage II or III, in whom a 
curative operation was assumed feasible 
preoperatively, including eight gastric cancers 
(stage II in two, stage III in six) and. six colon 
cancers (stage III in all), were eligible to this 
study. Changes in lymphocyte subsets were 
analyzed at the third day after 0. 1 KE 
intravenous administration of OK-432. Three 
times intravenous administration of 0.2 KE 
OK-432 was added in nine patients, consisted 
of five gastric cancers (stage II in one, stage 
III in four) and four colon cancers (stage II in 
one, stage III in three, to study the effects of 
OK-432 as an immunopotentiator. Cell prepara-
tion the blood samples were taken three days 
bef ore assessment of lymphocyte subset.
Peripheral blood mononuclear cell (PBM) were 
isolated by Ficoll-Hypaque density gradient 
sedimentation. The cells were suspended in the 
RPMI 1640 medium containing 10% pooled 
human AB serum, supplemented with penicillin 
100 pt /ml and streptomycin 100 ,u g/ml. 
 Lymphocyte subsets : Analysis of surfactant 
markers on lymphocyte subpopulations by 
monoclonal antibodies was performed accord-
ing to the method of STEPiHAN et al. 1) Analysis 
of fluorescence staining of cells was performed 
by means of single and two-color flow-cytome-
try using the FACS intervenous flow-cytome-
try system. Monoclonal antibodies used for 
phenotyping were CD3, CD4, CD8, CD20, CD11, 
Leu7, CD16, OK1a1, HLA-DR. Administration 
of OK-432 0.1 KE of OK-432 was intravenous-
ly given. At the third day, lymphocyte subsets 
were tested. In this preliminary study, however, 
it was found that an insufficient state of
immunostimulation has generated. Therefore, 
0.2 KE of OK-432 were given three times at an 
interval on three days as shown in Fig. 1.
Fig. 1. Schema of this study, upper : once, 0.1 
      KE OK-432 1V administration, thereafter
       3 days later flow cytometric analysis 
       was done. lower : 3 times 0.2 KE OK-432 
       1V at an interval of 3 days
         RESULTS 
 The results of intravenous administration 
of 0.1 KE of OK-432 were shown in Tabel 1. 
Each subset of lymphocytes did not change 
with varying variety. However, an increase in 
Leu7, and CD16 positive cells was remarkably 
noted, suggesting an action of immunopoten-
tiation.
Tabel 1. Changes in subset of lymphocytes 3 
        days after 0.1 KE OK-432 1V administ-
        ration
                    Percent positive cells 
n 
                    before 3 days after 
CD 3 14 64.4± 8.0 62.9± 9.1 
CD 4 14 43.0± 7.2 40.7± 9.8 
CD 8 14 27.3± 8.7 27.6± 7.8 
CD 20 14 16.7± 6.3 13.3± 4.6 
CD 11 14 28.8± 8.7 30.8±10.8 
               14 13.8± 7.8 16.6± 8.1 L
eu 7 12 11
.6± 5.4 16.0± 7.7*1 
               14 17.6± 8.6 18.4±10.9 CD16 
9 9.2± 4.1 16.4± 8.6*2 
OKIal 14 22.9± 8.4 21.5± 7.3 
HLA-DR 14 28.7± 8.2 27.0± 5.0
 On the other hand, when 0.2 KE of OK-432 
intervenous was given three times as shown in 
Table 2, the subsets of lymphocytes, CD20, CD 
11, Leu7, Ok1a1, HLA-DR and CD8, CD11 and 
CD4, 2H4 were markedly increased in number. 
Three times 0.2 KE OK-432 intervenous ad-
ministration fascilitated potentially an in-
Table 2. Changes in subset of lymphocytes 3 
        days after 3 time 0.2KE OK-432 1V 
        administration at an interval of 3 days
                    Percent positive cells 
n 
                    before 3 days after 
CD 3 9 66.2±10.1 65.8±14.3 
CD 4 9 42.5± 7.6 44.4±11.9 
CD 8 9 26.8± 5.1 .27.8± 6.1 
CD 20 9 10.8± 2.6 13.1± 4.5 f1 
CD 11 9 32.4± 9.2 41.6± 7.2?2 
Leu 7 9 19.6±11.5 24.0±10.4 q3 
CD 16 9 17.3±13.1 18.4± 9.3 
OK Ial 9 23.1± 9.8 34.4± 7.6 i4 
HLA-DR 9 21.4± 7.1 32.3± 7.215 
CD 8+ CD 11+ 5 8.0± 3.7 8.6± 4.2 
CD 8+ CD-11 5 17.0± 6.4 15.2± 6.6 f6 
CD4+ 4B4+ 5 24.8± 7.5 22.8± 9.5 
CD 4+ 2 H 4+ 5 14.4± 5.1 19.9± 8.3?~
crease in subpopulation of lymphocytes much 
more than 0.1 KE administration. An increase 
in activated T.B and NK cells was obviously 
noted to some extent in proportion to a dosis 
and an interval times of OK-432 administered. 
An increase in the population of these cells 
closely relates to the dosis, the frequency and 
the time-interval of OK-432 administration to 
immunodepressed tumor-bearing host. From 
an analysis by using two-color flow cytometry 
method, the effect of OK-432 on activation of 
lymphocytes was much more apparently shown 
than when compared with non-OK- 4 3 2 as 
indicated in Fig. 2 on the condition of 0..2 KE 
OK- 4 3 2 intravenous administration three 
times per three days intervals.
        DISCUSSION 
 Even in intravenous administration of OK-
4 3 2, the amount and frequency directly re-
lated to the stimulating effect on generation 
of activated subpopulation of T cells in PBM. 
 GFUMM et a12) showed that OK-432 induced 
cytotoxic cells after in vitro activation of 
PBM with the agent exhibited properties 
identical to LAK cells. Needless to say, LAK 
cells represent cytotoxic action for cancer cells, 
which are effectively acting as not only 
prevention of spread of cancer extension but 
also elimination of the tumor size. It is no
Fig. 2. Analysis of ajtivation of lymphocytes by using two 
       color flow eytometry method .
doubt that OK- 4 3 2 administration promotes 
generation of LAK cells. As a result,. the 
immunopotentiated host may help facilitate 
cancer therapy to give cytotoxic damage to 
cancer cells. It is widely accepted as previously 
cited by BusH's report 3) that a malignant 
human tumor regressed when the patient 
contracted erysipelas. Even though OK-432 
were given via intravenous route, the more the 
amount and the frequency of OK-432 were 
increased, the more generation of subset of 
activated lymphocytes in PBM was enhanced. 
 Interestingly enough, OK-432 administration 
arose generation of HLA-DR ( +) cells, which 
were composed of activated T, activated B and 
CD16 (Leulla). 
 In view of host-mediated immunopotentia-
tion by OK-432, OK-432 intervenous admin-
istration effectively promotes the activa-
tion of NK cells and also increases the number 
of activated T and B cells to make up for a 
depressed immune state of tumor-bearing host. 
 On the other hand, it is emphasized that OK-
432 reveals a direct cytotoxic effect on malig-
nant cells. In Japan endoscopical direct injec-
tion of OK-432 around cancer lesions has been 
applied for the treatment of cancers of the 
stomach and the lung. 4)5)
 Some reports cytologically evidenced direct 
cytotoxic effect on malignant cells.6) 7) For 
this advantage of this agent, OK-432 was used 
locally as a treatment of malignant pleural 
effusion and ascitic fluid, expecting the direct 
cytotoxic action of OK-432. 
 Cell damage to tumor cells by exposure to 
OK-432 is apparently presented in comparison 
with that prior to exposure to OK-432 by 
many investigators 6). 
 In contrast, it is defined that effectiveness 
of OK-432 in vivo observation closely corre-
lates with the response to SU-PS skin test"). 
SU-PS contains streptococcal protein. , There-
fore, the response to SU-PS skin-test reflects 
the reaction to a type of delayed hypersensitiv-
ity, showing a sensitized state to the antigen 
associated with streptocccal protein. It is 
clear that the. stronger the positive SU-PS 
skin test, the more the immune response of a 
host to cytotoxicity of cancer cells is enhanced. 
 In conclusion, OK-432 is effective in enhanc-
ing cell-mediated immunity to tumor-bearing 
host as well as in facilitating direct cytotoxi-
city to cancer cells when directly exposing to 
cancer cells.
          REFERENCE 
1) STEPHAN HI, RrTTERSHUS CW, HEALEY KW et al. 
   
: Rapid enumerativn of T lymphocytes by a 
   flow-cytometric immunofluorescence mehtod . 
   Clin. Chem. 28 : 1905-1910, 1982. 
2) GwMM EA, RAMSEY KM, MAZUMDEL A et al. 
   Lymph okine-activated killer cell pheno-
   menon. II Precursor phenotype is serologica-
   lly distinct from peripheral T lymphocytes , 
   memory cytotoxic thymus derived lymphocy-
   tes and natural killer cells. J exp . Med. 157: 
   884-897, 1983. 
3) BUSH W .: Verhandlungen aerzlichen gesell-
   schaften. Berl. Klin. Wochenschr. 5 :137-138 , 
  1858. 
4) KUMURA I, OHNrsr-rr T, YASUHARA S et al. : Im-
   munochemotherapy in human lung cancer 
   using the streptococcal agent OK-432. Cancer 
  37 : 2201-2203, 1976. 
5) UCHIDA A, HOSHINO T : Clinical studies on cell-
  mediated immunity in patients with malig-
   nant disease. I effect of immunotherapy with 
   OK-432 on lymphocyte subpopulation and 
   phytomitogen responsiveness in vitro. 
   Cancer 45 : 476-483, 1980. 
6) ONO T, KURATA S, WAKABAYASHI K et al .: Inhib-
   itory effect of a streptococcal preparation 
   (OK-432) on the nuclei acid symthesis in 
   tumor cells in vitro. Gann 64 : 59-69, 1973. 
7) SAKURAI Y, TSUKAGOSHr S, SATOH H et al . 
   Tumor -inhibitory effect of a streptococcal 
   preparation (NSC-B 116209). Cancer Che-
   mother Rep. 56 : 9-17, 1972. 
8) ATANABE Y, KOMORI Y, YAMADA T et al. 
   Clinical value of immunotherapy by strepto-
   coccal preparation. OK-432, as a posto-
   perative adjuvant therapy of lung cancer. 
  Jpn. J. Cancer Chemother 6 : 811-820, 1979. 
9) WATANABE Y, YAMADA T, KOBAYASHI H et al .: 
  Clinical significance of SU-polysaccharide 
   skin test as parameter for immunotherapy 
   with streptococcal preparation. OK-432. Jpn . 
  J. Can. Chemother 8 : 1076-1082 , 1981.
